In fact, somatic variants associated with leukemias had higher catalytic activity of SHP2, a more pronounced hypersensitivity to cytokines and growth factors, and a higher transformation potency than those that were non‐leukemia generating NS mutations (Keilhack et al., 2005). Here, PTPN11 is linked to leukemia.